TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+3.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.91B
AUM Growth
+$2.91B
(+2.1%)
Cap. Flow
+$57.4M
Cap. Flow
% of AUM
1.98%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
49
Closed
30
Top Buys
| 1 |
Elevance Health
ELV
|
$45.8M |
| 2 |
Abbott
ABT
|
$37.5M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$31.8M |
| 4 |
Moderna
MRNA
|
$29.3M |
| 5 |
Gilead Sciences
GILD
|
$26.5M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$59.8M |
| 2 |
Becton Dickinson
BDX
|
$21.5M |
| 3 |
Humana
HUM
|
$19.1M |
| 4 |
Bio-Techne
TECH
|
$16.8M |
| 5 |
NovoCure
NVCR
|
$15.2M |
Sector Composition
| 1 | Healthcare | 95.75% |
| 2 | Real Estate | 2.99% |
| 3 | Industrials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
BioMarin Pharmaceuticals
BMRN
$11.3B
| $9.67M | 0.33% |
128,004
-150,326
| -54% | -$11.4M |
|
77
Sarepta Therapeutics
SRPT
$1.98B
| $9.61M | 0.33% |
128,987
-77,500
| -38% | -$5.78M |
|
78
Universal Health Services
UHS
$11.6B
| $9.51M | 0.33% |
+71,323
| New | +$9.51M |
|
|
GTHX
79
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $9.43M | 0.32% |
+391,754
| New | +$9.43M |
|
80
Theravance Biopharma
TBPH
$691M
| $9.31M | 0.32% |
456,296
| – | – |
|
81
Molina Healthcare
MOH
$9.6B
| $9.3M | 0.32% |
39,769
| – | – |
|
|
GRTX
82
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $9.19M | 0.32% |
1,041,845
| – | – |
|
83
Zoetis
ZTS
$67.6B
| $8.9M | 0.31% |
56,521
| – | – |
|
84
Sabra Healthcare REIT
SBRA
$4.56B
| $8.87M | 0.3% |
510,660
| – | – |
|
85
Arrowhead Research
ARWR
$3.84B
| $8.81M | 0.3% |
132,886
| – | – |
|
86
Medical Properties Trust
MPW
$2.66B
| $8.76M | 0.3% |
411,743
| – | – |
|
|
DOC
87
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $8.76M | 0.3% |
495,733
| – | – |
|
88
Incyte
INCY
$17B
| $8.75M | 0.3% |
107,687
+14,430
| +15% | +$1.17M |
|
89
Denali Therapeutics
DNLI
$2.24B
| $8.57M | 0.29% |
150,086
+77,753
| +107% | +$4.44M |
|
90
Acadia Pharmaceuticals
ACAD
$4.34B
| $8.56M | 0.29% |
331,789
| – | – |
|
|
SAGE
91
DELISTED
Sage Therapeutics
SAGE
| $8.54M | 0.29% |
114,119
-37,921
| -25% | -$2.84M |
|
|
CTLT
92
DELISTED
CATALENT, INC.
CTLT
| $8.43M | 0.29% |
+80,025
| New | +$8.43M |
|
|
IMAB
93
I-MAB
IMAB
$380M
| $8.09M | 0.28% |
+166,896
| New | +$8.09M |
|
|
ITCI
94
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.89M | 0.27% |
232,476
-133,700
| -37% | -$4.54M |
|
95
Kura Oncology
KURA
$732M
| $7.73M | 0.27% |
273,463
| – | – |
|
96
Teva Pharmaceuticals
TEVA
$21.5B
| $7.62M | 0.26% |
660,551
-69,500
| -10% | -$802K |
|
|
LTC
97
LTC Properties
LTC
$1.67B
| $7.61M | 0.26% |
182,293
| – | – |
|
98
BioNTech
BNTX
$24.1B
| $7.51M | 0.26% |
+68,814
| New | +$7.51M |
|
|
CCXI
99
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.4M | 0.25% |
144,447
| – | – |
|
100
Boston Scientific
BSX
$159B
| $7.19M | 0.25% |
185,931
-60,158
| -24% | -$2.33M |
|